Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.